Skip to content
Oligon Logo

Oligon to Parcipate in the 9th Annual Fall Private Company Showcase
hosted by Solebury Trout, BMO and Goodwin

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Oligon™ Inc., an emerging biotechnology company developing a novel class of multimodal RNA therapeutics for the treatment of cancer and other diseases, announced today that Dr. Spyro Mousses, CEO and Co-Founder, Andrew Matricaria, CFO, and James Silver, COO, will participate in the 9th Annual Solebury Trout Fall Private Company Showcase co-hosted with BMO and Goodwin on October 13, 2022 in New York, NY.

All three will host one-on-one investor meetings at the showcase, and Dr. Mousses will present a company overview during a 4:20 P.M. EDT session as part of the Track 2 schedule.

About Oligon
Oligon™ is developing a new class of multimodal RNA therapeutics that can simultaneously silence numerous disease targets with a single RNA molecule to improve outcomes and combat emerging drug resistance. Our proprietary SeekR™ platform is used to digitally engineer and rapidly produce self-delivering therapeutics which target specific tissues with unprecedented precision and accuracy. We are focused on building a pipeline of products in oncology, yet our multimodal RNA platform can be harnessed to transform outcomes for any complex multigenic disease.
To schedule a meeting during this conference, please contact: